Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-10 ل  147 نتائج ل ""CTLA-4 Antigen""

فلترة النتائج

Publisher : public library of science
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Anti-CTLA-4 treatment suppresses hepatocellular carcinoma growth through Th1-mediated cell cycle arrest and apoptosis.

  • Authors : Morihara H; Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.; Laboratory for Bio-Drug Discovery, Shionogi & Co., Ltd., Osaka, Japan.

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/pathology ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/metabolism

  • Source: PloS one [PLoS One] 2024 Aug 06; Vol. 19 (8), pp. e0305984. Date of Electronic Publication: 2024 Aug 06 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Association of tuberculosis risk with genetic polymorphisms of the immune checkpoint genes PDCD1, CTLA-4, and TIM3.

  • Authors : Liu CW; Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.; Translational Medicine Center, Taoyuan General Hospital, Department of Health and Welfare, Taoyuan, Taiwan.

Subjects: CTLA-4 Antigen*/CTLA-4 Antigen*/CTLA-4 Antigen*/genetics ; Genetic Predisposition to Disease* ; Hepatitis A Virus Cellular Receptor 2*/Hepatitis A Virus Cellular Receptor 2*/Hepatitis A Virus Cellular Receptor 2*/genetics

  • Source: PloS one [PLoS One] 2024 May 09; Vol. 19 (5), pp. e0303431. Date of Electronic Publication: 2024 May 09 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors.

  • Authors : Sumimoto H; Department of Medical Oncology, Shiga University of Medical Science, Otsu, Shiga, Japan.; Cancer Center, Shiga University of Medical Science, Otsu, Shiga, Japan.

Subjects: Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/adverse effects ; Autoimmune Diseases*/Autoimmune Diseases*/Autoimmune Diseases*/chemically induced ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy

  • Source: PloS one [PLoS One] 2024 Jul 16; Vol. 19 (7), pp. e0306995. Date of Electronic Publication: 2024 Jul 16 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.

  • Authors : Khunger A; Department of Internal Medicine, Memorial Hospital West, Pembroke Pines, Florida, United States of America.; Piazza E

Subjects: Transcription, Genetic*/Transcription, Genetic*/Transcription, Genetic*/drug effects; CTLA-4 Antigen/CTLA-4 Antigen/CTLA-4 Antigen/*antagonists & inhibitors ; Inflammation/Inflammation/Inflammation/*genetics

  • Source: PloS one [PLoS One] 2021 Jan 11; Vol. 16 (1), pp. e0245287. Date of Electronic Publication: 2021 Jan 11 (Print Publication: 2021).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Detection of CTLA-4 level and humeral immune response after the second dose of COVID-19 vaccine in certain Iraqi provinces participants.

  • Authors : Al-Kaif LAIK; Department of Medical Microbiology, Hammurabi College of Medicine, University of Babylon, Hillah, Babylon, Iraq.; Department of Medical Laboratory Techniques, Al-Mustaqbal University, Hillah, Babylon, Iraq.

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; COVID-19 Vaccines* ; Immunity, Humoral*

  • Source: PloS one [PLoS One] 2024 Jan 05; Vol. 19 (1), pp. e0296521. Date of Electronic Publication: 2024 Jan 05 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Selective Upregulation of CTLA-4 on CD8+ T Cells Restricted by HLA-B*35Px Renders them to an Exhausted Phenotype in HIV-1 infection.

  • Authors : Elahi S; School of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.; Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada.

Subjects: Virus Replication*; CD8-Positive T-Lymphocytes/CD8-Positive T-Lymphocytes/CD8-Positive T-Lymphocytes/*immunology ; CTLA-4 Antigen/CTLA-4 Antigen/CTLA-4 Antigen/*metabolism

  • Source: PLoS pathogens [PLoS Pathog] 2020 Aug 06; Vol. 16 (8), pp. e1008696. Date of Electronic Publication: 2020 Aug 06 (Print Publication: 2020).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.

  • Authors : Iwata TN; Oncology Research Laboratories I, R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Sugihara K

Subjects: Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*pharmacology ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*drug therapy ; CTLA-4 Antigen/CTLA-4 Antigen/CTLA-4 Antigen/*immunology

  • Source: PloS one [PLoS One] 2019 Oct 01; Vol. 14 (10), pp. e0222280. Date of Electronic Publication: 2019 Oct 01 (Print Publication: 2019).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.

  • Authors : Colston E; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.; Grasela D

Subjects: CTLA-4 Antigen/CTLA-4 Antigen/CTLA-4 Antigen/*immunology ; HIV Infections/HIV Infections/HIV Infections/*drug therapy ; HIV-1/HIV-1/HIV-1/*immunology

  • Source: PloS one [PLoS One] 2018 Jun 07; Vol. 13 (6), pp. e0198158. Date of Electronic Publication: 2018 Jun 07 (Print Publication: 2018).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.

  • Authors : Kassardjian A; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.; Shintaku PI

Subjects: Biomarkers, Tumor*; B7-H1 Antigen/B7-H1 Antigen/B7-H1 Antigen/*genetics ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*genetics

  • Source: PloS one [PLoS One] 2018 Apr 19; Vol. 13 (4), pp. e0195958. Date of Electronic Publication: 2018 Apr 19 (Print Publication: 2018).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.

  • Authors : Gombos RB; Immuno-modulatory Drug Discovery, Agenus Incorporated, Lexington, Massachusetts, United States of America.; Gonzalez A

Subjects: Adjuvants, Immunologic/Adjuvants, Immunologic/Adjuvants, Immunologic/*pharmacology ; Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*pharmacology ; CTLA-4 Antigen/CTLA-4 Antigen/CTLA-4 Antigen/*immunology

  • Source: PloS one [PLoS One] 2018 Apr 04; Vol. 13 (4), pp. e0191926. Date of Electronic Publication: 2018 Apr 04 (Print Publication: 2018).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-10 ل  147 نتائج ل ""CTLA-4 Antigen""